Access, Guidelines, and the Gap in Personalized Medicine w/ Dr. Federico Monzon

What does personalized medicine really mean—and why does it remain so difficult to implement at scale?

In this episode, Perry is joined by longtime colleague and molecular pathology expert Dr. Frederico Monzon for an in-depth conversation on the realities behind personalized medicine. Drawing from his experience across academia, clinical practice, and industry, Frederico reframes personalized medicine as not only identifying the right treatment—but also avoiding therapies that offer no benefit and may cause harm.

In this episode, you’ll hear about:

• How personalized medicine has long existed in pathology, even before the term became a buzzword
  
  
  
• Why avoiding ineffective treatments is just as critical as finding the right one
  
  
  
• The ongoing challenge of access to diagnostic testing and actionable information
  
  
  
• Why many patients still aren’t tested—even when guidelines and coverage exist
  
  
  
• The role of clinical guidelines as guardrails, not rigid rules
  
  
  
• Tensions and opportunities between laboratories, insurers, and lab benefit managers
  
  
  
• How unmet clinical need drives meaningful innovation in diagnostics
  
  
  
• Why collaboration across industry, academia, and payers is essential
  
  
  
• What excites Frederico most about the future: multimodal medicine combining genomics, pathology, imaging, clinical data, and AI
  
  
  

The conversation closes with a forward-looking discussion on how breaking down data silos—and using AI responsibly—could help healthcare teams deliver more precise, cost-effective care tailored to each individual patient.

—-------

Stay connected with our host, Perry Dimas, here on LinkedIn!

 
 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com

 🔗 Connect on LinkedIn: linkedin.com/company/accessdx